Loading…
Loading…
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LEO and 80,000+ other tickers.
See exactly how LEO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LEO and 80,000+ other tickers.
BNY Mellon Strategic Municipals, Inc. is a closed ended fixed income mutual fund launched and managed by BNY Mellon Investment Adviser, Inc. It invests in the fixed income markets of the United States. The fund primarily invests in investment grade municipal bonds, the income from which is exempt from federal income tax. It employs fundamental analysis to create its portfolio. The fund was formerly known as Dreyfus Strategic Municipals, Inc. BNY Mellon Strategic Municipals, Inc. was formed on September 23, 1987 and is domiciled in the United States.
Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, today announced a strategic investment in nextâgeneration phas
TAMPA, Fla.--(BUSINESS WIRE)--Sypris Electronics, LLC, a subsidiary of Sypris Solutions, Inc. (Nasdaq/GM: SYPR), announced today that it has received an award from a leading space technologies company to support the non-recurring engineering, material procurement, and high-volume manufacturing of power processing units for a next-generation satellite constellation. Production under the agreement includes protoflight and pilot builds beginning in Q3 2026, followed by phased delivery of flight un.
VinSpace Joint Stock Company ("VinSpace") announced the signing of a launch contract with U.S.-basedSpaceX. The agreement marks a significant milestone in VinSp
Danish drugmaker LEO Pharma said on Tuesday it had agreed to acquire worldwide rights to drug candidate dersimelagon from Tanabe Pharma for up to $435 million in up-front and near-term milestone payments.
MDA SPACE SATELLITES FOR GLOBALSTAR SUCCESSFULLY LAUNCHED PR Newswire TORONTO, Aug. 16, 2026